Predictive Oncology
Eagan
About Predictive Oncology
Predictive Oncology operates through three segments (Skyline, Helomics and Soluble Biotech), which contain four subsidiaries: Helomics, TumorGenesis, Skyline Medical and Soluble Biotech. Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: Less than $1M
- Total funding: $437.8M
- Funding stage: IPO
- Last round: Post-IPO Equity (Sep 2025)
- Ticker: nasdaq:POAI
- Website: predictive-oncology.com
Industries & Categories
Health Care, Health Diagnostics, Medical, Oncology, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/predictive-oncology-42750 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.